BioMarin Pharmaceutical Inc. (BMRN)
$
53
-0.70 (-1.32%)
Key metrics
Financial statements
Free cash flow per share
4.3293
Market cap
10.7 Billion
Price to sales ratio
3.4713
Debt to equity
0.0985
Current ratio
4.8276
Income quality
1.7562
Average inventory
1.4 Billion
ROE
0.0884
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
BioMarin Pharmaceutical Inc. specializes in the development and commercialization of therapies aimed at addressing serious and life-threatening rare diseases and medical conditions. The company’s portfolio includes Vimizim, an enzyme replacement therapy for mucopolysaccharidosis (MPS) IV type A; Naglazyme, a recombinant enzyme for treating MPS VI; and Kuvan, a synthetic oral treatment for phenylketonuria (PKU). Additionally, the product lineup features Palynziq, which is a PEGylated recombinant enzyme administered via subcutaneous injection to lower blood Phe levels; Brineura, designed for ceroid lipofuscinosis type 2; and Voxzogo, a daily injection aimed at treating achondroplasia. Another key product, Aldurazyme, is a purified protein mimicking the natural human enzyme alpha-L-iduronidase. BioMarin is also progressing with valoctocogene roxaparvovec in Phase III trials for severe hemophilia A, BMN 307 in Phase 1/2 trials for PKU, and BMN 255 in Phase 1/2 trials targeting primary hyperoxaluria. The total costs and expenses for the company are $2,369,701,000.00 reflecting its overall spending. The gross profit ratio is 0.80 indicating the efficiency of the company's production and sales operations. Furthermore, the company recorded a net income of $426,859,000.00 highlighting its profitability. Depreciation and amortization expenses of $96,426,000.00 are reported, reflecting the wear and tear of its assets, against a substantial revenue of $2,853,915,000.00 showcasing its strong market presence. As a publicly traded entity, BioMarin's stock is reasonably priced at $54.36 appealing to a broad range of investors. The stock maintains a high average trading volume of 2,677,879.00 indicating robust liquidity. With a mid-range market capitalization of $10,182,060,232.00 the company is recognized as a steady performer. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, BioMarin operates within the Healthcare sector, driving innovation and growth, which positions it favorably among its peers. This dynamic combination of product offerings and market strategies underscores BioMarin's commitment to enhancing the lives of patients facing rare diseases.
Is BioMarin Pharmaceutical Inc. (BMRN) a good investment?
Investing in BioMarin Pharmaceutical Inc. (BMRN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
What is BioMarin Pharmaceutical Inc. (BMRN)'s stock forecast?
Analysts predict BioMarin Pharmaceutical Inc. stock to fluctuate between $50.76 (low) and $73.51 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is BioMarin Pharmaceutical Inc.'s market capitalization?
As of 2025-12-11, BioMarin Pharmaceutical Inc.'s market cap is $10,182,060,232, based on 192,114,344 outstanding shares.
How does BioMarin Pharmaceutical Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., BioMarin Pharmaceutical Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy BioMarin Pharmaceutical Inc. (BMRN) stock?
To buy BioMarin Pharmaceutical Inc. (BMRN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for BMRN. Place an order (Market, Limit, etc.).
What is the best time to invest in BioMarin Pharmaceutical Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did BioMarin Pharmaceutical Inc. perform in the last earnings report?
Revenue: $2,853,915,000 | EPS: $2.25 | Growth: 152.81%.
Where can I find BioMarin Pharmaceutical Inc.'s investor relations reports?
Visit https://www.biomarin.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for BioMarin Pharmaceutical Inc.?
You can explore historical data from here
What is the all-time high and low for BioMarin Pharmaceutical Inc. stock?
All-time high: $117.77 (2023-01-27) | All-time low: $50.76 (2025-11-07).
What are the key trends affecting BioMarin Pharmaceutical Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
BioMarin Pharmaceutical Inc. ( BMRN ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Day 2 of our London Healthcare Conference. Great to see everyone.
zacks.com
BMRN tops Q3 earnings expectations but misses on sales. The company moves to divest its hemophilia gene therapy, Roctavian.
seekingalpha.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q3 2025 Earnings Call October 27, 2025 4:30 PM EDT Company Participants Traci McCarty - Group Vice President Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Philip Nadeau - TD Cowen, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Julian Pino Christopher Raymond - Raymond James & Associates, Inc., Research Division Sean Laaman - Morgan Stanley, Research Division Presentation Operator Hello, and welcome to the BioMarin Pharmaceutical Third Quarter 2025 Conference Call. [Operator Instructions].
247wallst.com
BioMarin Pharmaceutical (Nasdaq: BMRN) missed both revenue and earnings estimates in the third quarter, and yet, shares are up 1% in after-hours trading.
zacks.com
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
reuters.com
BioMarin Pharmaceutical said on Monday it plans to divest its gene therapy, a product once expected to be a blockbuster treatment for a type of rare bleeding disorder.
zacks.com
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to earnings of $0.91 per share a year ago.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
seekingalpha.com
BioMarin has both a solid revenue portfolio of several products and a promising pipeline. The market's main concern has been TransCon competition; however, the combination of Voxzogo and BMN 333 could effectively fight back. Even if the U.S. government were to regulate prices, it would only affect a small portion of the company, since 64% of its sales originate outside the US.
See all news
